



# AbbVie (ABBV)

Updated May 3<sup>rd</sup>, 2021 by Jonathan Weber

## Key Metrics

<b>Current Price:</b>	\$115	<b>5 Year CAGR Estimate:</b>	8.7%	<b>Market Cap:</b>	\$207B
<b>Fair Value Price:</b>	\$125	<b>5 Year Growth Estimate:</b>	3.0%	<b>Ex-Dividend Date:</b>	07/14/21 <sup>1</sup>
<b>% Fair Value:</b>	92%	<b>5 Year Valuation Multiple Estimate:</b>	1.6%	<b>Dividend Payment Date:</b>	08/16/21 <sup>2</sup>
<b>Dividend Yield:</b>	4.5%	<b>5 Year Price Target</b>	\$145	<b>Years Of Dividend Growth:</b>	49
<b>Dividend Risk Score:</b>	A	<b>Retirement Suitability Score:</b>	A	<b>Last Dividend Increase:</b>	10.2%

## Overview & Current Events

AbbVie is a biotechnology company focused on developing and commercializing drugs for immunology, oncology and virology. AbbVie was spun off by Abbott Laboratories in 2013. The company has a rather short stand-alone history. Nevertheless, AbbVie has become one of the largest players in the biotechnology industry, especially following the closing of its acquisition of formerly independent pharma company Allergan.

AbbVie reported its first quarter earnings results on April 30. The company was able to generate revenues of \$13.0 billion during the quarter, which was 51% more than AbbVie's revenues during the previous year's quarter. AbbVie generated higher revenues than the analyst community had forecasted, as it beat the top line consensus by \$230 million. AbbVie's revenues were positively impacted by healthy growth from some of its drugs, including Skyrizi and Rinvoq, but even more so by the addition of Allergan, which was taken over by AbbVie and which impacted the year-over-year revenue growth rate meaningfully.

AbbVie earned \$2.95 per share during the first quarter, which was 22% more than the company's earnings-per-share during the previous year's quarter. AbbVie's earnings-per-share also beat the consensus analyst estimate by \$0.12. AbbVie's guidance for 2021's adjusted earnings-per-share was updated and raised during the earnings call, the company expects to earn \$12.37 - \$12.57 on a per-share basis this year, which would represent a sizeable increase versus 2020, which had also be a record year already, despite the pandemic.

## Growth on a Per-Share Basis

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2026
<b>EPS</b>	---	---	\$3.14	\$3.32	\$4.29	\$4.82	\$5.60	\$7.91	\$8.94	\$10.56	<b>\$12.47</b>	<b>\$14.46</b>
<b>DPS</b>	---	---	\$0.80	\$1.66	\$2.02	\$2.28	\$2.56	\$3.59	\$4.28	\$4.72	<b>\$5.20</b>	<b>\$6.64</b>
<b>Shares<sup>3</sup></b>	---	---	1590	1590	1610	1590	1590	1550	1490	1780	<b>1800</b>	<b>1750</b>

AbbVie's explosive earnings-per-share growth started shortly after the company was spun off from Abbott Laboratories in 2013. Since then, earnings-per-share have grown by 15% annually. 2018 was a year of outsized earnings-per-share growth, partially driven by a lower tax rate, but also by ongoing growth from some of the company's largest drugs.

AbbVie's efforts in shielding Humira from competition through 2023 (in the US) and its substantial R&D investments for next-generation drugs should allow the company to keep revenues growing over the coming years. Humira's patent expiry in the US is still a couple of years away, which gives AbbVie enough time to bring new drugs to the market. AbbVie's new, improved drugs that target the same indications as Humira have a good chance at capturing much of Humira's current revenue stream. AbbVie's management believes that company-wide revenues in 2025 will be higher than they were in 2020, despite the fact that Humira's revenues will be much lower in the mid-2020s. The acquisition of Allergan, which has closed in 2020, will also drive future revenue growth and diversify the company further, which will soften the blow from the eventual generic competition for Humira, the world's best-selling drug.

<sup>1</sup> Estimated date

<sup>2</sup> Estimated date

<sup>3</sup> In Millions

*Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.*



# AbbVie (ABBV)

Updated May 3<sup>rd</sup>, 2021 by Jonathan Weber

## Valuation Analysis

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	Now	2026
Avg. P/E	---	---	13.9	16.7	14.4	12.6	13.4	11.6	10.0	9.9	<b>9.2</b>	<b>10.0</b>
Avg. Yld.	---	---	3.7%	3.0%	3.3%	3.8%	3.4%	4.8%	4.8%	4.5%	<b>4.5%</b>	<b>4.6%</b>

AbbVie's share price has risen substantially since our last update, but the company's shares still trade at a rather inexpensive valuation. The increased leverage due to the Allergan deal and the Humira patent expiry a couple of years from now result in some risks, which is why we believe that a price-to-earnings multiple of around 10 seems fair. AbbVie looks marginally undervalued at the current price. AbbVie's shares are offering a high dividend yield to its owners.

## Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2026
Payout	---	---	25.5%	50.0%	47.1%	47.3%	45.7%	45.4%	47.9%	44.7%	<b>41.7%</b>	<b>45.9%</b>


AbbVie started to pay dividends in 2013, and since then, the payout has risen quickly. This was possible due to a combination of strong earnings-per-share growth and an increase in AbbVie's dividend payout ratio. AbbVie does not have a very long dividend growth track record on its own, but we believe that its dividend looks relatively safe.

The healthcare industry, and especially the drug industry, is not very cyclical. AbbVie was not a standalone company during the last financial crisis, so there is no recession track record, but since sick people require treatment whether the economy is strong or not, it is highly likely that AbbVie will continue to perform well during recessions. AbbVie's Humira patent protection in the US will expire in a couple of years, but Humira will remain a major cash cow for now. Thanks to next-generation drugs and the takeover of Allergan, there is a good chance that the patent expiration will not be too much of a headwind. Investors should note that the Humira patent situation provides some uncertainty nevertheless.

## Final Thoughts & Recommendation

AbbVie is a leading biotech and pharma company that has grown both its profits as well as its dividend at a strong pace in the past. The Humira patent situation could pressure revenues in 2023-2025, but we believe that the outlook is still positive, thanks to a deep pipeline, strong growth from new drugs, and the Allergan acquisition that allows for the capturing of some synergies between the two companies. Shares look slightly undervalued and offer a strong yield and substantial total returns, which is why we rate AbbVie a hold at current prices.

## Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# AbbVie (ABBV)

Updated May 3<sup>rd</sup>, 2021 by Jonathan Weber

## Income Statement Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
<b>Revenue</b>	17444	18380	18790	19960	22859	25638	28216	32753	33266	45804
<b>Gross Profit</b>	12805	13872	14209	15534	18359	19806	21174	25035	25827	30417
<b>Gross Margin</b>	73.4%	75.5%	75.6%	77.8%	80.3%	77.3%	75.0%	76.4%	77.6%	66.4%
<b>SG&amp;A Exp.</b>	5894	4989	5352	7724	6387	5881	6295	7399	6942	11299
<b>D&amp;A Exp.</b>	1272	1150	897	786	836	1189	1501	1765	2017	6471
<b>Operating Profit</b>	4293	6105	6002	3763	7687	9540	9872	6807	13368	12561
<b>Op. Margin</b>	24.6%	33.2%	31.9%	18.9%	33.6%	37.2%	35.0%	20.8%	40.2%	27.4%
<b>Net Profit</b>	3433	5275	4128	1774	5144	5953	5309	5687	7882	4616
<b>Net Margin</b>	19.7%	28.7%	22.0%	8.9%	22.5%	23.2%	18.8%	17.4%	23.7%	10.1%
<b>Free Cash Flow</b>	5891	6012	5776	2937	7003	6562	9431	12789	12772	16790
<b>Income Tax</b>	235	450	1204	595	1501	1931	2418	(490)	544	(1224)

## Balance Sheet Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
<b>Total Assets</b>	19521	27008	29198	27513	53050	66099	70786	59352	89115	150565
<b>Cash &amp; Equivalents</b>	27	5901	9595	8348	8399	5100	9303	7289	39924	8449
<b>Acc. Receivable</b>	3817	4298	3854	3735	4730	4758	5088	5384	5428	8822
<b>Inventories</b>	872	1091	1150	1124	1719	1444	1605	1605	1813	3310
<b>Goodwill &amp; Int.</b>	9010	8453	8167	7375	32877	44313	43344	36896	34253	116000
<b>Total Liabilities</b>	7589	23645	24706	25771	49105	61463	65689	67798	97287	137468
<b>Accounts Payable</b>	417	556	933	1401	1597	1407	1474	1546	1452	2276
<b>Long-Term Debt</b>	48	15672	14723	14977	31671	36842	37368	40310	66728	86056
<b>Total Equity</b>	11932	3363	4492	1742	3945	4636	5097	(8446)	(8172)	13076
<b>D/E Ratio</b>	0.00	4.66	3.28	8.60	8.03	7.95	7.33	(4.77)	(8.17)	6.58

## Profitability & Per Share Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
<b>Return on Assets</b>	16.9%	22.7%	14.7%	6.3%	12.8%	10.0%	7.8%	8.7%	10.6%	3.9%
<b>Return on Equity</b>	24.8%	69.0%	105%	56.9%	181%	139%	109%			188%
<b>ROIC</b>	24.8%	34.0%	21.6%	9.9%	19.7%	15.4%	12.6%	15.3%	17.4%	5.9%
<b>Shares Out.</b>	---	---	1590	1590	1610	1590	1590	1550	1490	1780
<b>Revenue/Share</b>	11.04	11.66	11.71	12.40	13.96	15.72	17.60	21.19	22.42	27.38
<b>FCF/Share</b>	3.73	3.81	3.60	1.82	4.28	4.02	5.88	8.27	8.61	10.04

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

### Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.